ClinicalTrials.gg
CompletedNCT02948959VOYAGEUpdated Mar 28, 2022Results posted

Evaluation of Dupilumab in Children With Uncontrolled Asthma

A Phase 3 interventional study of Dupilumab and Placebo in Asthma, sponsored by Sanofi. Completed at 99 sites in 18 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2022-03-28.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.

Enrollment
6th of 31
408 · median 120
Started
2017
with 1 other
Phase 3
11 of 31
2 open now
Registered
7th of 31
by date
Lead sponsor
15 of 31
Sanofi

Among the 31 studies testing dupilumab in Asthma, this one is the 6th largest by enrollment, is one of 2 that started in 2017, is one of 11 in phase 3, and was the 7th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing dupilumab in Asthma, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the efficacy of dupilumab in children 6 to less than (\<) 12 years of age with uncontrolled persistent asthma.

Secondary Objective:

To evaluate in children 6 to \<12 years of age with uncontrolled persistent asthma:

  • The safety and tolerability of dupilumab.
  • The evaluate the effect of dupilumab in improving participant reported outcomes including health related quality of life.
  • The dupilumab systemic exposure and incidence of anti-drug antibodies.
  • The evaluate the association between dupilumab treatment and pediatric immune responses to vaccines: any vaccination for tetanus, diphtheria, pertussis and/or seasonal trivalent/quadrivalent influenza vaccine.
Read the detailed description

The total study duration per participant was up to 69 weeks, consisted of a screening period of 3-5 weeks, a randomized treatment period of 52 weeks and a post-treatment period of 12 weeks.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Children 6 to \<12 years of age, with a physician diagnosis of persistent asthma for greater than or equal to (>=)12 months prior to screening, based on clinical history and examination, pulmonary function parameters according to Global initiative for asthma (GINA) 2015 Guidelines and the following criteria:

  • Existing background therapy of medium-dose ICS with second controller medication (i.e., long-acting β2 agonist , leukotriene receptor antagonist, long acting muscarinic antagonist, or methylxanthines) or high-dose ICS alone or high-dose ICS with second controller, for at least 3 months with a stable dose >=1 month prior to Screening Visit 1.
  • Pre-bronchodilator (FEV1) \<=95 percentage (%) of predicted normal or pre bronchodilator FEV1/forced vital capacity ratio \<0.85 at Screening and Baseline Visits.
  • Reversibility of at least 10% in FEV1 after the administration of 200 to 400 micrograms (mcg; 2 to 4 puff inhalations with metered-dose inhaler [MDI]) of albuterol/salbutamol or 45 to 90 mcg (2 to 4 puffs with MDI) of levalbuterol/levosalbutamol reliever medication before randomization (up to 3 opportunities during the same visit were allowed with a maximum of 12 puffs of reliever medication if tolerated by the participant).
  • Must had experienced, within 1 year prior to Screening Visit 1, any of the following events:

    • Treatment with a systemic (oral or parenteral), as prescribed by a healthcare professional for worsening asthma at least once or,
    • Hospitalization or emergency visit for worsening asthma.
  • Evidence of uncontrolled asthma, with at least one of the following criteria during the 4 (±1) weeks Screening Period:

    • Asthma Control Questionnaire-Interviewer Administered (ACQ-IA) ACQ-5 score >=1.5 on at least one day of the Screening Period.
    • Use of reliever medication (i.e., albuterol/salbutamol or levalbuterol/levosalbutamol), other than as a preventive for exercise induced bronchospasm, on 3 or more days per week, in at least one week during the Screening Period.
    • Sleep awakening due to asthma symptoms requiring use of reliever medication at least once during the Screening Period.
    • Asthma symptoms 3 or more days per week in at least one week during the Screening Period.

Exclusion criteria

Exclusion criteria:

  • Participants \<6 or >=12 years of age.
  • Participants with \<16 kg bodyweight.
  • Any other chronic lung disease (cystic fibrosis, bronchopulmonary dysplasia, etc.), which may impair lung function.
  • A participant with any history of life threatening asthma (ie, extreme exacerbation that requires intubation).
  • Co-morbid disease that might interfere with the evaluation of medicinal product.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
408 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo (for Dupilumab), subcutaneous (SC) injection every 2 weeks (q2w) for 52 weeks in combination with stable-dose background therapy of medium-dose inhaled corticosteroids (ICS) with a second controller medication (i.e., long-acting β2 agonist \[LABA\], long acting muscarinic antagonist \[LAMA\], leukotriene receptor antagonist \[LTRA\] or methylxanthines) or high-dose ICS alone or high-dose ICS with second controller medication. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication. Participants were followed up for 12 weeks after last dose (i.e. up to Week 64).

    Drug: Placebo · Drug: Asthma Controller Therapies · Drug: Asthma Reliever Therapies

  • Experimental
    Dupilumab

    Dupilumab 200 milligrams (mg) (in 1.14 milliliters \[mL\] for \>30 kilograms \[kg\] bodyweight \[BW\]) or 100 mg (in 0.67 mL for less than or equal to (\<=) 30 kg BW), SC injection q2w for 52 weeks in combination with stable-dose background therapy of medium-dose ICS with a second controller medication (i.e., LABA, LAMA, LTRA\] or methylxanthines) or high-dose ICS alone or high-dose ICS with second controller medication. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication. Participants were followed up for 12 weeks after last dose (i.e. up to Week 64).

    Drug: Dupilumab · Drug: Asthma Controller Therapies · Drug: Asthma Reliever Therapies

Interventions

  • Pharmaceutical form: Solution Route of administration: Subcutaneous

    Also known as: SAR231893 (REGN668)

  • DrugPlacebo

    Pharmaceutical form: Solution Route of administration: Subcutaneous

  • DrugAsthma Controller Therapies

    Pharmaceutical form: Aerosol, capsules, tablets, oral solution Route of administration: Inhaled, oral

  • DrugAsthma Reliever Therapies

    Pharmaceutical form: Nebulized, aerosol Route of administration: Inhaled

06

What researchers measure

Primary outcomes

  1. Annualized Rate of Severe Exacerbation Events During the 52-Week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    A severe asthma exacerbation event was defined as a deterioration of asthma during the 52-week treatment period requiring: use of systemic corticosteroids for \>=3 days; and/or hospitalization or emergency room visit because of asthma requiring systemic corticosteroid treatment. Annualized event rate was defined as the total number of severe exacerbation events that occurred during the 52-week treatment period divided by the total number of participant-years followed in the 52-week treatment period.

    Time frame: Baseline to Week 52

  2. Annualized Rate of Severe Exacerbation Events During the 52-Week Treatment Period: Type 2 Inflammatory Asthma Phenotype Population

    A severe asthma exacerbation event was defined as a deterioration of asthma during the 52-week treatment period requiring: use of systemic corticosteroids for \>=3 days; and/or hospitalization or emergency room visit because of asthma requiring systemic corticosteroid treatment. Annualized event rate was defined as the total number of severe exacerbation events that occurred during the 52-week treatment period divided by the total number of participant-years followed in the 52-week treatment period.

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Change From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 (FEV1) Second at Week 12: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator % predicted FEV1 value up to Week 12 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Week 12

  2. Change From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 12: Type 2 Inflammatory Asthma Phenotype Population

    FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Least square (LS) means and standard error (SE) were derived from mixed-effect model with repeated measures (MMRM) model with change from baseline in pre-bronchodilator % predicted FEV1 value up to Week 12 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Week 12

  3. Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version (ACQ-7-IA) at Week 24: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    ACQ-7-IA had 7 questions, which assessed: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities, shortness of breath due to asthma and wheeze, reliever medication use, and FEV1 (% predicted). Participants recalled their previous week asthma and answered 5 symptom questions on 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). Total score: mean of scores of all 7 questions; ranging from 0 (totally controlled) to 6 (severely uncontrolled), higher score indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-7-IA values up to Week 52 as response variable and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-7-IA value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Week 24

  4. Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version at Week 24: Type 2 Inflammatory Asthma Phenotype Population

    ACQ-7-IA had 7 questions, which assessed: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities due to asthma, shortness of breath due to asthma and wheeze, reliever medication use, and FEV1 (% predicted). Participants recalled their previous week asthma and answered 5 symptom questions on 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). Total score: mean of scores of all 7 questions; ranging from 0 (totally controlled) to 6 (severely uncontrolled), higher score indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-7-IA values up to Week 52 as response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-7-IA value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Week 24

  5. Change From Baseline in Fractional Exhaled Nitric Oxide Level at Week 12: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    FeNO is a surrogate marker for airway inflammation. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 mL/second, and reported in ppb. LS means and SE were derived from MMRM model with change from baseline in FeNO up to Week 12 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline ICS level, visit, treatment by-visit interaction, baseline FeNO value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Week 12

  6. Change From Baseline in Fractional Exhaled Nitric Oxide Level at Week 12: Type 2 Inflammatory Asthma Phenotype Population

    FeNO is a surrogate marker for airway inflammation. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 mL/second, and reported in ppb. LS means and SE were derived from MMRM model with change from baseline in FeNO up to Week 12 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline ICS level, visit, treatment by-visit interaction, baseline FeNO value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Week 12

  7. Change From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second at Weeks 2, 4, 8, 24, 36 and 52: Type 2 Inflammatory Asthma Phenotype Population

    FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator % predicted FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 24, 36, 52

  8. Change From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second at Weeks 2, 4, 8, 24, 36 and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator % predicted FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 24, 36, 52

  9. Time to First Severe Exacerbation Event: Kaplan-Meier Estimates During 52-week Treatment Period: Type 2 Inflammatory Asthma Phenotype Population

    The time to first severe exacerbation was defined as date of the first severe exacerbation event - randomization date +1. A severe asthma exacerbation event was defined as a deterioration of asthma during the 52-week treatment period requiring: use of systemic corticosteroids for \>=3 days; and/or hospitalization related to asthma symptoms or emergency room visit because of asthma requiring systemic corticosteroid treatment. Kaplan-Meier method was used for analysis.

    Time frame: Baseline up to Week 52

  10. Time to First Severe Exacerbation Event: Kaplan-Meier Estimates During 52-week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    The time to first severe exacerbation was defined as date of the first severe exacerbation event - randomization date +1. A severe asthma exacerbation event was defined as a deterioration of asthma during the 52-week treatment period requiring: use of systemic corticosteroids for \>=3 days; and/or hospitalization related to asthma symptoms or emergency room visit because of asthma requiring systemic corticosteroid treatment. Kaplan-Meier method was used for analysis.

    Time frame: Baseline up to Week 52

  11. Time to First Loss of Asthma Control (LOAC) Event: Kaplan-Meier Estimates During 52-week Treatment Period: Type 2 Inflammatory Asthma Phenotype Population

    Time to first LOAC event was date of first LOAC event - first dose date +1. A LOAC event was defined as deterioration of asthma during 52-week treatment period that resulted in any of the following: \>= 6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in 24-hour period (compared to baseline) on 2 consecutive days; increase in ICS dose \>=4 times than dose at Visit 2 (Week 0); a decrease in ante meridiem (AM)/post meridiem (PM) peak flow of 30% or more on 2 consecutive days of treatment, based on defined stability limit (defined as respective mean AM/PM peak expiratory flow obtained over last 7 days prior to randomization (Day 1); severe exacerbation event. Kaplan-Meier method was used for analysis.

    Time frame: Baseline up to Week 52

  12. Time to First Loss of Asthma Control Event: Kaplan-Meier Estimates During 52-week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    Time to first LOAC event was date of first LOAC event - first dose date +1. A LOAC event was defined as deterioration of asthma during 52-week treatment period that resulted in any of the following: \>= 6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in 24-hour period (compared to baseline) on 2 consecutive days; increase in ICS dose \>=4 times than dose at Visit 2 (Week 0); a decrease in AM/PM peak flow of 30% or more on 2 consecutive days of treatment, based on defined stability limit (defined as respective mean AM/PM peak expiratory flow obtained over last 7 days prior to randomization (Day 1); severe exacerbation event. Kaplan-Meier method was used for analysis.

    Time frame: Baseline up to Week 52

  13. Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, 52: Type 2 Inflammatory Asthma Phenotype Population

    FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator FEV1 values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline pre-bronchodilator FEV1 value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  14. Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator FEV1 values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline pre-bronchodilator FEV1 value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  15. Percent Change From Baseline in Pre-Bronchodilator Percent Predicted FEV1 at Weeks 2, 4, 8, 12, 24, 36, 52: Type 2 Inflammatory Asthma Phenotype Population

    FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator % predicted FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  16. Percent Change From Baseline in Pre-Bronchodilator Percent Predicted FEV1 at Weeks 2, 4, 8, 12, 24, 36, 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator % predicted FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  17. Change From Baseline in Morning (AM) Peak Expiratory Flow (PEF) at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population

    The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for AM PEF was performed in morning prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol reliever medication. Baseline AM PEF was the mean AM measurement recorded for the 7 days prior to the first dose of investigational product. LS means and SE were derived from MMRM model with change from baseline in AM PEF (liters/minute) values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline AM PEF (liters/minute) value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  18. Change From Baseline in Evening (PM) Peak Expiratory Flow at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population

    The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PM PEF was performed in evening prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol reliever medication. Baseline PM PEF was the mean PM measurement recorded for the 7 days prior to the first dose of investigational product. LS means and SE were derived from MMRM model with change from baseline in PM PEF (liters/minute) values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PM PEF (liters/minute) value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  19. Change From Baseline in Morning (AM) Peak Expiratory Flow at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for AM PEF was performed in morning prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol reliever medication. Baseline AM PEF was the mean AM measurement recorded for the 7 days prior to the first dose of investigational product. LS means and SE were derived from MMRM model with change from baseline in AM PEF (liters/minute) values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline AM PEF (liters/minute) value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  20. Change From Baseline in Evening (PM) Peak Expiratory Flow at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PM PEF was performed in evening prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol reliever medication. Baseline PM PEF was the mean PM measurement recorded for the 7 days prior to the first dose of investigational product. LS means and SE were derived from MMRM model with change from baseline in PM PEF (liters/minute) values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PM PEF (liters/minute) value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  21. Change From Baseline in Forced Vital Capacity (FVC) at Weeks 2, 4, 8, 12, 24, 36, 52: Type 2 Inflammatory Asthma Phenotype Population

    FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position, measured in liters. LS means and SE were derived from MMRM model with change from baseline in FVC values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline FVC value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  22. Change From Baseline in Forced Vital Capacity at Weeks 2, 4, 8, 12, 24, 36, 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position, measured in liters. LS means and SE were derived from MMRM model with change from baseline in FVC values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline FVC value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  23. Change From Baseline in Forced Expiratory Flow (FEF) 25-75% at Weeks 2, 4, 8, 12, 24, 36, 52: Type 2 Inflammatory Asthma Phenotype Population

    FEF is the amount of air (in liters) which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% was defined as the mean FEF between 25% and 75% of the FVC, where FVC was defined as the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. LS means and SE were derived from MMRM model with change from baseline in FEF 25-75% values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline FEF 25-75% value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  24. Change From Baseline in Forced Expiratory Flow 25-75% at Weeks 2, 4, 8, 12, 24, 36, 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    FEF is the amount of air (in liters) which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% was defined as the mean FEF between 25% and 75% of the FVC, where FVC was defined as the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. LS means and SE were derived from MMRM model with change from baseline in FE F25-75% values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline FEF 25-75% value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  25. Change From Baseline in Post-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population

    Participants were assessed for post-bronchodilator FEV1 30 minutes after bronchodilator administration (200 to 400 mg \[2 to 4 puffs\] of albuterol/salbutamol or 45 to 90 micrograms \[2 to 4 puffs\] of levalbuterol/levosalbutamol). FEV1 was the volume of air (in liters) exhaled in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in post-bronchodilator FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline post-bronchodilator FEV1 value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  26. Change From Baseline in Post-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    Participants were assessed for post-bronchodilator FEV1 30 minutes after bronchodilator administration (200 to 400 mg \[2 to 4 puffs\] of albuterol/salbutamol or 45 to 90 micrograms \[2 to 4 puffs\] of levalbuterol/levosalbutamol). FEV1 was the volume of air (in liters) exhaled in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in post-bronchodilator FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline post-bronchodilator FEV1 value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  27. Change From Baseline in Morning Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population

    The morning asthma symptom score evaluated participant's overall asthma symptoms experienced during the previous night. It ranged from 0 (no asthma symptoms, slept through the night) to 4 (bad night, awake most of the night because of asthma), where lower scores indicate more mild symptoms and higher scores indicate more severe symptoms. LS means and SE were derived from MMRM model with change from baseline in AM asthma symptom score values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline AM asthma symptom score value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  28. Change From Baseline in Evening Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population

    The evening asthma symptom score evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 (very well, no asthma symptoms) to 4 (asthma very bad, unable to carry out daily activities as usual), where lower scores indicate more mild symptoms and higher scores indicate more severe symptoms. LS means and SE were derived from MMRM model with change from baseline in PM asthma symptom score values up to Week 52 as response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PM asthma symptom score value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  29. Change From Baseline in Morning Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    The morning asthma symptom score evaluated participant's overall asthma symptoms experienced during the previous night. It ranged from 0 (no asthma symptoms, slept through the night) to 4 (bad night, awake most of the night because of asthma), where lower scores indicate more mild symptoms and higher scores indicate more severe symptoms. LS means and SE were derived from MMRM model with change from baseline in AM asthma symptom score values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline AM asthma symptom score value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  30. Change From Baseline in Evening Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    The evening asthma symptom score evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 (very well, no asthma symptoms) to 4 (asthma very bad, unable to carry out daily activities as usual), where lower scores indicate more mild symptoms and higher scores indicate more severe symptoms. LS means and SE were derived from MMRM model with change from baseline in PM asthma symptom score values up to Week 52 as response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PM asthma symptom score value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  31. Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 5-question Version (ACQ-5-IA) at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population

    ACQ-5-IA has 5 questions, reflecting top-scoring 5 asthma symptoms: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities, shortness of breath due to asthma and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). ACQ-5-IA total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), higher scores indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-5-IA values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-5-IA value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  32. Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 5-question Version at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    ACQ-5-IA has 5 questions, reflecting top-scoring 5 asthma symptoms: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities, shortness of breath due to asthma and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). ACQ-5-IA total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), higher scores indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-5-IA values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-5-IA value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  33. Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version at Weeks 2, 4, 8, 12, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    ACQ-7-IA had 7 questions, assessed: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities, shortness of breath due to asthma and wheeze, reliever medication use, and FEV1 (% predicted). Participants recalled their previous week asthma and answered 5 symptom questions on 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). Total score:mean of scores of all 7 questions; ranging from 0 (totally controlled) to 6 (severely uncontrolled), higher score indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-7-IA values up to Week 52 as response variable and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-7-IA value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8,12, 36, 52

  34. Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version at Weeks 2, 4, 8, 12, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population

    ACQ-7-IA had 7 questions, assessed: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities due to asthma, shortness of breath due to asthma and wheeze, reliever medication use, and FEV1 (% predicted). Participants recalled their previous week asthma and answered 5 symptom questions on 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). Total score: mean of scores of all 7 questions; ranging from 0 (totally controlled) to 6 (severely uncontrolled), higher score indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-7-IA values up to Week 52 as response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-7-IA value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8,12, 36, 52

  35. Change From Baseline in Number of Puffs of Reliever Medication Used Per 24 Hours at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population

    Participants might be administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed. Number of reliever medication inhalations were recorded daily in electronic diary/PEF meter. When Nebulizer solutions were used as alternative delivery method, nebulizer dose was converted to number of puffs as per conversion factor: salbutamol/albuterol nebulizer solution (2.5 mg) and levosalbutamol/levalbuterol (1.25 mg) corresponds to 4 puffs. Change From Baseline in number of puffs of reliever medication used per 24 hours at specified weeks was reported. LS means and SE were derived from MMRM model with change from baseline in number of puffs of reliever medication/24 hours values up to Week 52 as response variable and treatment, age, baseline: weight group, region, eosinophil level, FeNO level, ICS dose level, visit, treatment by-visit interaction, baseline number of puffs of reliever medication/24 hours value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  36. Change From Baseline in Number of Puffs of Reliever Medication Used Per 24 Hours at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    Participants might be administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed. Number of reliever medication inhalations were recorded daily in electronic diary/PEF meter. When Nebulizer solutions were used as alternative delivery method, nebulizer dose was converted to number of puffs as per conversion factor: salbutamol/albuterol nebulizer solution (2.5 mg) and levosalbutamol/levalbuterol (1.25 mg) corresponds to 4 puffs. Change From Baseline in number of puffs of reliever medication used per 24 hours at specified weeks was reported. LS means and SE were derived from MMRM model with change from baseline in number of puffs of reliever medication/24 hours values up to Week 52 as response variable and treatment, age, baseline: weight group, region, eosinophil level, FeNO level, ICS dose level, visit, treatment by-visit interaction, baseline number of puffs of reliever medication/24 hours value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  37. Change From Baseline in Number of Nocturnal Awakenings Per Night at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population

    Participants recorded every morning the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night. Change from baseline in number of nocturnal awakenings per night at specified weeks was reported. LS means and SE were derived from MMRM model with change from baseline in number of nocturnal awakenings values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline number of nocturnal awakenings value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  38. Change From Baseline in Number of Nocturnal Awakenings Per Night at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    Participants recorded every morning the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night. Change from baseline in number of nocturnal awakenings per night at specified weeks was reported. LS means and SE were derived from MMRM model with change from baseline in number of nocturnal awakenings values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline number of nocturnal awakenings value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 52

  39. Change From Baseline in Pediatric Asthma Quality of Life (QoL) Questionnaire With Standardized Activities-Interviewer Administered (PAQLQ[S] IA) Scores at Weeks 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population

    PAQLQ(S)-IA, a disease-specific, interviewer-administered QoL questionnaire designed to measure functional impairments that are most important to children \>=7 years with asthma. The PAQLQ(S)-IA comprises of 23 items in 3 domains: symptoms (10 items), activity limitation (5 items) and emotional function (8 items). Each item was scored on a 7-point likert scale (1=maximal impairment to 7=no impairment). 23 items of questionnaire were averaged to produce 1 overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all), higher scores indicated better quality of life. LS means and SE were derived from MMRM model with change from baseline in PAQLQ(S)-IA global score values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PAQLQ(S)-IA global score value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 12, 24, 36, 52

  40. Change From Baseline in Pediatric Asthma Quality of Life Questionnaire With Standardized Activities-Interviewer Administered Scores at Weeks 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    PAQLQ(S)-IA, a disease-specific, interviewer-administered QoL questionnaire designed to measure functional impairments that are most important to children \>=7 years with asthma. The PAQLQ(S)-IA comprises of 23 items in 3 domains: symptoms (10 items), activity limitation (5 items) and emotional function (8 items). Each item was scored on a 7-point likert scale (1=maximal impairment to 7=no impairment). 23 items of questionnaire were averaged to produce 1 overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all), higher scores indicated better quality of life. LS means and SE were derived from MMRM model with change from baseline in PAQLQ(S)-IA global score values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PAQLQ(S)-IA global score value and baseline-by-visit interaction as covariates.

    Time frame: Baseline, Weeks 12, 24, 36, 52

  41. Healthcare Resource Utilization (HCRU): Number of School and Work Days Missed Due to LOAC: Type 2 Inflammatory Asthma Phenotype Population

    The number of days missed from school by the participant and the number of days missed from work by the caregiver of participant due to a LOAC were collected in the electronic-case report form (eCRF). Cumulative number of missed days (school days and work days) up to week 52 were computed and summarized using mean and standard deviation (SD).

    Time frame: Baseline to Week 52

  42. Healthcare Resource Utilization: Number of School and Work Days Missed Due to LOAC: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    The number of days missed from school by the participant and the number of days missed from work by the caregiver of participant due to a LOAC were collected in the eCRF. Cumulative number of missed days (school days and work days) up to week 52 were computed and summarized using mean and SD.

    Time frame: Baseline to Week 52

  43. Healthcare Resource Utilization: Percentage of Participants Who Had Missed Greater Than or Equal to 5 School/Work Days Due to LOAC: Type 2 Inflammatory Asthma Phenotype Population

    The number of days missed from school for the participant and the missed number of days from work for the caregiver due to a LOAC were collected in the eCRF. The percentage of participants who had at least 5 days (school days and work days) missed due to LOAC over the study period was reported.

    Time frame: Baseline to Week 52

  44. Healthcare Resource Utilization: Percentage of Participants Who Had Missed Greater Than or Equal to 5 School/Work Days Due to LOAC: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

    The number of days missed from school for the participant and the missed number of days from work for the caregiver due to a LOAC were collected in the eCRF. The percentage of participants who had at least 5 days (school days and work days) missed due to LOAC over the study period was reported.

    Time frame: Baseline to Week 52

  45. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    Adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and did not necessary have to had a causal relationship with treatment.TEAEs were defined as AEs that developed or worsened in grade or became serious during TEAE period which was defined as the period from the time of first dose of study drug to the end of post-treatment period. A serious adverse events (SAE) was any untoward medical occurrence that at any dose resulted in: death; or life-threatening experience; or required inpatient hospitalization or prolongation of existing hospitalization; or resulted in persistent or significant disability/incapacity; or was a congenital anomaly/birth defect or a medically important event. TEAEs included both SAEs and non-SAEs.

    Time frame: From Baseline up to Week 64

  46. Pharmacokinetics (PK) Assessment: Functional Dupilumab Concentration in Serum

    Data for this outcome measure was planned to be collected and analyzed separately for dupilumab 100 mg and 200 mg dose and not planned to be collected and analyzed for placebo arm.

    Time frame: Baseline, Weeks 6, 12, 24, 52, 64

  47. Percentage of Participants With Treatment Emergent Antidrug Antibodies (ADA) Response

    ADA response was categorized as: treatment emergent and treatment boosted response. 1) Treatment emergent was defined as an ADA positive response in the assay post first dose, when baseline results were negative or missing. 2) Treatment boosted was defined as: an ADA positive response in the assay post first dose that was greater-than or equal to 4-fold over baseline titer levels, when baseline results were positive. The criteria for positive was defined as "30 to \> 10,000", where low titer (\< 1,000); moderate (1,000 \<= titer \<= 10,000) and high titer (\> 10,000).

    Time frame: From Baseline up to Week 64

  48. Percentage of Participants With Seroconversion

    Seroconversion was defined as a post-vaccination titer \>=40 (1/dilution) for those with a pre-vaccination titer \<10 (1/dilution), or a \>= 4-fold increase in post-vaccination titer for those with a pre-vaccination titer \>=10 (1/dilution).

    Time frame: From Baseline up to Week 64

07

Results

Posted Oct 20, 2021

Participant flow

The study was conducted at 90 active centers in 17 countries. A total of 631 participants were screened between 21 April 2017 and 22 July 2019, of which 408 participants were enrolled and randomized to receive dupilumab or placebo. A total of 223 participants failed screening mainly due to failure to meet inclusion criteria.

52 Weeks Treatment Period
Participant flow — 52 Weeks Treatment Period
MilestonePlaceboDupilumab
Started135273
Treated135270
Safety population134271
Type 2 inflammatory asthma phenotype population114236
Baseline blood eosinophils count >=300 cells per microlitre population84175
Completed130248
Not completed525
Withdrew: Poor compliance to protocol02
Withdrew: Adverse event25
Withdrew: Withdrawal by subject22
Withdrew: Participant used protocol prohibited vaccine16
Withdrew: Randomized by error05
Withdrew: Randomized and not treated03
Withdrew: Non-compliant to study treatment01
Withdrew: Change of residence location01
12 Weeks Follow-up Period
Participant flow — 12 Weeks Follow-up Period
MilestonePlaceboDupilumab
Started931
Completed419
Not completed512
Withdrew: Adverse event02
Withdrew: Poor compliance to protocol12
Withdrew: Withdrawal by subject33
Withdrew: Randomized by error03
Withdrew: Change of residence location02
Withdrew: Study site closure10

Outcome measures

PrimaryAnnualized Rate of Severe Exacerbation Events During the 52-Week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

A severe asthma exacerbation event was defined as a deterioration of asthma during the 52-week treatment period requiring: use of systemic corticosteroids for \>=3 days; and/or hospitalization or emergency room visit because of asthma requiring systemic corticosteroid treatment. Annualized event rate was defined as the total number of severe exacerbation events that occurred during the 52-week treatment period divided by the total number of participant-years followed in the 52-week treatment period.

Time frame:
Baseline to Week 52
Reported as:
Number · exacerbations per participant-years
Annualized Rate of Severe Exacerbation Events During the 52-Week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
exacerbations per participant-yearsPlaceboDupilumab
Annualized Rate of Severe Exacerbation Events During the 52-Week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population0.665 (0.467 to 0.949)0.235 (0.160 to 0.345)
Statistical analysis
  • Placebo vs Dupilumab · Negative binomial model · p = <0.0001 (Threshold for statistical significance at 5% significant level.) · Risk ratio (rr): 0.353 · 95% CI 0.222 to 0.562Risk ratio, also called relative risk compares the risk (rate) of an event among one group with the risk (rate) among another group.
PrimaryAnnualized Rate of Severe Exacerbation Events During the 52-Week Treatment Period: Type 2 Inflammatory Asthma Phenotype Population

A severe asthma exacerbation event was defined as a deterioration of asthma during the 52-week treatment period requiring: use of systemic corticosteroids for \>=3 days; and/or hospitalization or emergency room visit because of asthma requiring systemic corticosteroid treatment. Annualized event rate was defined as the total number of severe exacerbation events that occurred during the 52-week treatment period divided by the total number of participant-years followed in the 52-week treatment period.

Time frame:
Baseline to Week 52
Reported as:
Number · exacerbations per participant-years
Annualized Rate of Severe Exacerbation Events During the 52-Week Treatment Period: Type 2 Inflammatory Asthma Phenotype Population
exacerbations per participant-yearsPlaceboDupilumab
Annualized Rate of Severe Exacerbation Events During the 52-Week Treatment Period: Type 2 Inflammatory Asthma Phenotype Population0.748 (0.542 to 1.034)0.305 (0.223 to 0.416)
Statistical analysis
  • Placebo vs Dupilumab · Negative binomial model · p = <0.0001 (Threshold for statistical significance at 5% significant level.) · Risk ratio (rr): 0.407 · 95% CI 0.274 to 0.605Risk ratio, also called relative risk compares the risk (rate) of an event among one group with the risk (rate) among another group.
SecondaryChange From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 (FEV1) Second at Week 12: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator % predicted FEV1 value up to Week 12 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent predicted FEV1
Change From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 (FEV1) Second at Week 12: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
percent predicted FEV1PlaceboDupilumab
Change From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 (FEV1) Second at Week 12: Baseline Blood Eosinophils >=300 Cells Per Microliter Population4.83 ± 1.5410.15 ± 1.12
Statistical analysis
  • Placebo vs Dupilumab · Mixed-effect model with repeated measure · p = 0.0036 (Threshold for statistical significance at 5% significant level.) · Ls mean difference: 5.32 · 95% CI 1.76 to 8.88
SecondaryChange From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 12: Type 2 Inflammatory Asthma Phenotype Population

FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Least square (LS) means and standard error (SE) were derived from mixed-effect model with repeated measures (MMRM) model with change from baseline in pre-bronchodilator % predicted FEV1 value up to Week 12 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent predicted FEV1
Change From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 12: Type 2 Inflammatory Asthma Phenotype Population
percent predicted FEV1PlaceboDupilumab
Change From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 12: Type 2 Inflammatory Asthma Phenotype Population5.32 ± 1.3610.53 ± 1.01
Statistical analysis
  • Placebo vs Dupilumab · Mixed-effect model with repeated measure · p = 0.0009 (Threshold for statistical significance at 5% significant level.) · Ls mean difference: 5.21 · 95% CI 2.14 to 8.27
SecondaryChange From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version (ACQ-7-IA) at Week 24: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

ACQ-7-IA had 7 questions, which assessed: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities, shortness of breath due to asthma and wheeze, reliever medication use, and FEV1 (% predicted). Participants recalled their previous week asthma and answered 5 symptom questions on 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). Total score: mean of scores of all 7 questions; ranging from 0 (totally controlled) to 6 (severely uncontrolled), higher score indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-7-IA values up to Week 52 as response variable and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-7-IA value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version (ACQ-7-IA) at Week 24: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
score on a scalePlaceboDupilumab
Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version (ACQ-7-IA) at Week 24: Baseline Blood Eosinophils >=300 Cells Per Microliter Population-0.88 ± 0.09-1.34 ± 0.06
Statistical analysis
  • Placebo vs Dupilumab · Mixed-effect model with repeated measure · p = <0.0001 (Threshold for statistical significance at 5% significant level.) · Ls mean difference: -0.46 · 95% CI -0.66 to -0.26
SecondaryChange From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version at Week 24: Type 2 Inflammatory Asthma Phenotype Population

ACQ-7-IA had 7 questions, which assessed: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities due to asthma, shortness of breath due to asthma and wheeze, reliever medication use, and FEV1 (% predicted). Participants recalled their previous week asthma and answered 5 symptom questions on 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). Total score: mean of scores of all 7 questions; ranging from 0 (totally controlled) to 6 (severely uncontrolled), higher score indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-7-IA values up to Week 52 as response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-7-IA value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version at Week 24: Type 2 Inflammatory Asthma Phenotype Population
score on a scalePlaceboDupilumab
Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version at Week 24: Type 2 Inflammatory Asthma Phenotype Population-0.99 ± 0.07-1.32 ± 0.05
Statistical analysis
  • Placebo vs Dupilumab · Mixed-effect model with repeated measure · p = 0.0001 (Threshold for statistical significance at 5% significant level.) · Ls mean difference: -0.33 · 95% CI -0.50 to -0.16
SecondaryChange From Baseline in Fractional Exhaled Nitric Oxide Level at Week 12: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

FeNO is a surrogate marker for airway inflammation. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 mL/second, and reported in ppb. LS means and SE were derived from MMRM model with change from baseline in FeNO up to Week 12 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline ICS level, visit, treatment by-visit interaction, baseline FeNO value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · parts per billion
Change From Baseline in Fractional Exhaled Nitric Oxide Level at Week 12: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
parts per billionPlaceboDupilumab
Change From Baseline in Fractional Exhaled Nitric Oxide Level at Week 12: Baseline Blood Eosinophils >=300 Cells Per Microliter Population-0.81 ± 1.69-21.40 ± 1.21
Statistical analysis
  • Placebo vs Dupilumab · Mixed-effect model with repeated measure · p = <0.0001 (Threshold for statistical significance at 5% significant level.) · Ls mean difference: -20.59 · 95% CI -24.60 to -16.59
SecondaryChange From Baseline in Fractional Exhaled Nitric Oxide Level at Week 12: Type 2 Inflammatory Asthma Phenotype Population

FeNO is a surrogate marker for airway inflammation. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 mL/second, and reported in ppb. LS means and SE were derived from MMRM model with change from baseline in FeNO up to Week 12 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline ICS level, visit, treatment by-visit interaction, baseline FeNO value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · parts per billion
Change From Baseline in Fractional Exhaled Nitric Oxide Level at Week 12: Type 2 Inflammatory Asthma Phenotype Population
parts per billionPlaceboDupilumab
Change From Baseline in Fractional Exhaled Nitric Oxide Level at Week 12: Type 2 Inflammatory Asthma Phenotype Population-1.13 ± 1.43-18.97 ± 1.04
Statistical analysis
  • Placebo vs Dupilumab · Mixed-effect model with repeated measure · p = <0.0001 (Threshold for statistical significance at 5% significant level.) · Ls mean difference: -17.84 · 95% CI -21.05 to -14.63
SecondaryChange From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second at Weeks 2, 4, 8, 24, 36 and 52: Type 2 Inflammatory Asthma Phenotype Population

FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator % predicted FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 24, 36, 52
Reported as:
Least squares mean · percent predicted FEV1
Change From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second at Weeks 2, 4, 8, 24, 36 and 52: Type 2 Inflammatory Asthma Phenotype Population
percent predicted FEV1PlaceboDupilumab
Change at Week 24.84 ± 1.298.11 ± 0.95
Change at Week 43.55 ± 1.309.97 ± 0.97
Change at Week 84.27 ± 1.2910.27 ± 0.96
Change at Week 244.27 ± 1.4010.92 ± 1.04
Change at Week 366.63 ± 1.4911.46 ± 1.10
Change at Week 524.36 ± 1.5012.15 ± 1.10
SecondaryChange From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second at Weeks 2, 4, 8, 24, 36 and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator % predicted FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 24, 36, 52
Reported as:
Least squares mean · percent predicted of FEV1
Change From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second at Weeks 2, 4, 8, 24, 36 and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
percent predicted of FEV1PlaceboDupilumab
Change at Week 23.94 ± 1.517.49 ± 1.08
Change at Week 42.19 ± 1.539.09 ± 1.12
Change at Week 82.48 ± 1.429.75 ± 1.04
Change at Week 243.45 ± 1.6311.10 ± 1.19
Change at Week 366.87 ± 1.8111.47 ± 1.31
Change at Week 524.08 ± 1.8012.43 ± 1.30
SecondaryTime to First Severe Exacerbation Event: Kaplan-Meier Estimates During 52-week Treatment Period: Type 2 Inflammatory Asthma Phenotype Population

The time to first severe exacerbation was defined as date of the first severe exacerbation event - randomization date +1. A severe asthma exacerbation event was defined as a deterioration of asthma during the 52-week treatment period requiring: use of systemic corticosteroids for \>=3 days; and/or hospitalization related to asthma symptoms or emergency room visit because of asthma requiring systemic corticosteroid treatment. Kaplan-Meier method was used for analysis.

Time frame:
Baseline up to Week 52
Reported as:
Median · days
Time to First Severe Exacerbation Event: Kaplan-Meier Estimates During 52-week Treatment Period: Type 2 Inflammatory Asthma Phenotype Population
daysPlaceboDupilumab
Time to First Severe Exacerbation Event: Kaplan-Meier Estimates During 52-week Treatment Period: Type 2 Inflammatory Asthma Phenotype PopulationNA (366.00 to NA)NA (NA to NA)
SecondaryTime to First Severe Exacerbation Event: Kaplan-Meier Estimates During 52-week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

The time to first severe exacerbation was defined as date of the first severe exacerbation event - randomization date +1. A severe asthma exacerbation event was defined as a deterioration of asthma during the 52-week treatment period requiring: use of systemic corticosteroids for \>=3 days; and/or hospitalization related to asthma symptoms or emergency room visit because of asthma requiring systemic corticosteroid treatment. Kaplan-Meier method was used for analysis.

Time frame:
Baseline up to Week 52
Reported as:
Median · days
Time to First Severe Exacerbation Event: Kaplan-Meier Estimates During 52-week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
daysPlaceboDupilumab
Time to First Severe Exacerbation Event: Kaplan-Meier Estimates During 52-week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population366.0 (265.00 to NA)NA (NA to NA)
SecondaryTime to First Loss of Asthma Control (LOAC) Event: Kaplan-Meier Estimates During 52-week Treatment Period: Type 2 Inflammatory Asthma Phenotype Population

Time to first LOAC event was date of first LOAC event - first dose date +1. A LOAC event was defined as deterioration of asthma during 52-week treatment period that resulted in any of the following: \>= 6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in 24-hour period (compared to baseline) on 2 consecutive days; increase in ICS dose \>=4 times than dose at Visit 2 (Week 0); a decrease in ante meridiem (AM)/post meridiem (PM) peak flow of 30% or more on 2 consecutive days of treatment, based on defined stability limit (defined as respective mean AM/PM peak expiratory flow obtained over last 7 days prior to randomization (Day 1); severe exacerbation event. Kaplan-Meier method was used for analysis.

Time frame:
Baseline up to Week 52
Reported as:
Median · days
Time to First Loss of Asthma Control (LOAC) Event: Kaplan-Meier Estimates During 52-week Treatment Period: Type 2 Inflammatory Asthma Phenotype Population
daysPlaceboDupilumab
Time to First Loss of Asthma Control (LOAC) Event: Kaplan-Meier Estimates During 52-week Treatment Period: Type 2 Inflammatory Asthma Phenotype Population63.5 (42.00 to 84.00)140.0 (103.00 to 217.00)
SecondaryTime to First Loss of Asthma Control Event: Kaplan-Meier Estimates During 52-week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

Time to first LOAC event was date of first LOAC event - first dose date +1. A LOAC event was defined as deterioration of asthma during 52-week treatment period that resulted in any of the following: \>= 6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in 24-hour period (compared to baseline) on 2 consecutive days; increase in ICS dose \>=4 times than dose at Visit 2 (Week 0); a decrease in AM/PM peak flow of 30% or more on 2 consecutive days of treatment, based on defined stability limit (defined as respective mean AM/PM peak expiratory flow obtained over last 7 days prior to randomization (Day 1); severe exacerbation event. Kaplan-Meier method was used for analysis.

Time frame:
Baseline up to Week 52
Reported as:
Median · days
Time to First Loss of Asthma Control Event: Kaplan-Meier Estimates During 52-week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
daysPlaceboDupilumab
Time to First Loss of Asthma Control Event: Kaplan-Meier Estimates During 52-week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population47.5 (38.00 to 84.00)135.0 (82.00 to 219.00)
SecondaryAbsolute Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, 52: Type 2 Inflammatory Asthma Phenotype Population

FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator FEV1 values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline pre-bronchodilator FEV1 value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · liters
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, 52: Type 2 Inflammatory Asthma Phenotype Population
litersPlaceboDupilumab
Change at Week 20.08 ± 0.030.14 ± 0.02
Change at Week 40.06 ± 0.030.18 ± 0.02
Change at Week 80.09 ± 0.030.21 ± 0.02
Change at Week 120.12 ± 0.030.22 ± 0.02
Change at Week 240.14 ± 0.030.27 ± 0.02
Change at Week 360.23 ± 0.030.33 ± 0.02
Change at Week 520.24 ± 0.030.41 ± 0.02
SecondaryAbsolute Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator FEV1 values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline pre-bronchodilator FEV1 value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · liters
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
litersPlaceboDupilumab
Change at Week 20.07 ± 0.030.13 ± 0.02
Change at Week 40.04 ± 0.030.17 ± 0.02
Change at Week 80.06 ± 0.030.20 ± 0.02
Change at Week 120.12 ± 0.030.22 ± 0.02
Change at Week 240.13 ± 0.030.28 ± 0.03
Change at Week 360.24 ± 0.040.33 ± 0.03
Change at Week 520.25 ± 0.040.42 ± 0.03
SecondaryPercent Change From Baseline in Pre-Bronchodilator Percent Predicted FEV1 at Weeks 2, 4, 8, 12, 24, 36, 52: Type 2 Inflammatory Asthma Phenotype Population

FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator % predicted FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Pre-Bronchodilator Percent Predicted FEV1 at Weeks 2, 4, 8, 12, 24, 36, 52: Type 2 Inflammatory Asthma Phenotype Population
percent changePlaceboDupilumab
Change at Week 28.07 ± 2.0013.38 ± 1.47
Change at Week 46.73 ± 2.1016.01 ± 1.55
Change at Week 87.68 ± 1.8716.33 ± 1.41
Change at Week 128.87 ± 2.1016.94 ± 1.56
Change at Week 247.66 ± 2.1217.61 ± 1.57
Change at Week 3610.88 ± 2.8519.19 ± 2.06
Change at Week 527.92 ± 2.8120.06 ± 2.03
SecondaryPercent Change From Baseline in Pre-Bronchodilator Percent Predicted FEV1 at Weeks 2, 4, 8, 12, 24, 36, 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in pre-bronchodilator % predicted FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline % predicted FEV1 value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Pre-Bronchodilator Percent Predicted FEV1 at Weeks 2, 4, 8, 12, 24, 36, 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
percent changePlaceboDupilumab
Change at Week 27.55 ± 2.4112.76 ± 1.73
Change at Week 45.81 ± 2.5715.20 ± 1.87
Change at Week 86.09 ± 2.1016.01 ± 1.56
Change at Week 129.56 ± 2.4517.14 ± 1.79
Change at Week 247.44 ± 2.5418.09 ± 1.85
Change at Week 3612.15 ± 3.6719.65 ± 2.61
Change at Week 528.50 ± 3.5820.97 ± 2.54
SecondaryChange From Baseline in Morning (AM) Peak Expiratory Flow (PEF) at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population

The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for AM PEF was performed in morning prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol reliever medication. Baseline AM PEF was the mean AM measurement recorded for the 7 days prior to the first dose of investigational product. LS means and SE were derived from MMRM model with change from baseline in AM PEF (liters/minute) values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline AM PEF (liters/minute) value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · liters/minute
Change From Baseline in Morning (AM) Peak Expiratory Flow (PEF) at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population
liters/minutePlaceboDupilumab
Change at Week 25.57 ± 2.666.50 ± 2.00
Change at Week 47.10 ± 3.3112.81 ± 2.43
Change at Week 87.37 ± 3.5618.05 ± 2.59
Change at Week 125.37 ± 3.9319.38 ± 2.85
Change at Week 248.76 ± 4.5323.32 ± 3.25
Change at Week 3617.70 ± 4.9926.77 ± 3.56
Change at Week 5219.88 ± 5.1631.45 ± 3.69
SecondaryChange From Baseline in Evening (PM) Peak Expiratory Flow at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population

The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PM PEF was performed in evening prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol reliever medication. Baseline PM PEF was the mean PM measurement recorded for the 7 days prior to the first dose of investigational product. LS means and SE were derived from MMRM model with change from baseline in PM PEF (liters/minute) values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PM PEF (liters/minute) value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · liters/minute
Change From Baseline in Evening (PM) Peak Expiratory Flow at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population
liters/minutePlaceboDupilumab
Change at Week 27.62 ± 2.9410.60 ± 2.20
Change at Week 46.92 ± 3.4215.23 ± 2.52
Change at Week 85.52 ± 3.6020.17 ± 2.64
Change at Week 121.71 ± 3.9219.68 ± 2.85
Change at Week 243.78 ± 4.6122.75 ± 3.32
Change at Week 3612.55 ± 5.0624.69 ± 3.62
Change at Week 5216.46 ± 5.2028.20 ± 3.73
SecondaryChange From Baseline in Morning (AM) Peak Expiratory Flow at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for AM PEF was performed in morning prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol reliever medication. Baseline AM PEF was the mean AM measurement recorded for the 7 days prior to the first dose of investigational product. LS means and SE were derived from MMRM model with change from baseline in AM PEF (liters/minute) values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline AM PEF (liters/minute) value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · liters/minute
Change From Baseline in Morning (AM) Peak Expiratory Flow at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
liters/minutePlaceboDupilumab
Change at Week 25.85 ± 2.977.94 ± 2.21
Change at Week 45.62 ± 3.8011.75 ± 2.76
Change at Week 85.54 ± 4.0917.32 ± 2.96
Change at Week 124.77 ± 4.6519.25 ± 3.34
Change at Week 244.78 ± 5.0523.62 ± 3.61
Change at Week 3614.80 ± 5.7726.78 ± 4.08
Change at Week 5219.75 ± 6.3332.80 ± 4.49
SecondaryChange From Baseline in Evening (PM) Peak Expiratory Flow at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PM PEF was performed in evening prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol reliever medication. Baseline PM PEF was the mean PM measurement recorded for the 7 days prior to the first dose of investigational product. LS means and SE were derived from MMRM model with change from baseline in PM PEF (liters/minute) values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PM PEF (liters/minute) value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · liters/minute
Change From Baseline in Evening (PM) Peak Expiratory Flow at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
liters/minutePlaceboDupilumab
Change at Week 25.64 ± 3.4210.02 ± 2.53
Change at Week 44.36 ± 3.9613.09 ± 2.89
Change at Week 80.92 ± 4.0517.51 ± 2.96
Change at Week 12-1.37 ± 4.5717.73 ± 3.30
Change at Week 24-1.37 ± 5.2120.30 ± 3.74
Change at Week 367.52 ± 6.0123.23 ± 4.26
Change at Week 5214.67 ± 6.3926.60 ± 4.54
SecondaryChange From Baseline in Forced Vital Capacity (FVC) at Weeks 2, 4, 8, 12, 24, 36, 52: Type 2 Inflammatory Asthma Phenotype Population

FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position, measured in liters. LS means and SE were derived from MMRM model with change from baseline in FVC values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline FVC value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · liters
Change From Baseline in Forced Vital Capacity (FVC) at Weeks 2, 4, 8, 12, 24, 36, 52: Type 2 Inflammatory Asthma Phenotype Population
litersPlaceboDupilumab
Change at Week 20.07 ± 0.020.07 ± 0.02
Change at Week 40.07 ± 0.030.11 ± 0.02
Change at Week 80.10 ± 0.020.13 ± 0.02
Change at Week 120.12 ± 0.030.14 ± 0.02
Change at Week 240.16 ± 0.030.20 ± 0.02
Change at Week 360.22 ± 0.030.28 ± 0.02
Change at Week 520.27 ± 0.030.37 ± 0.02
SecondaryChange From Baseline in Forced Vital Capacity at Weeks 2, 4, 8, 12, 24, 36, 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position, measured in liters. LS means and SE were derived from MMRM model with change from baseline in FVC values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline FVC value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · liters
Change From Baseline in Forced Vital Capacity at Weeks 2, 4, 8, 12, 24, 36, 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
litersPlaceboDupilumab
Change at Week 20.07 ± 0.030.06 ± 0.02
Change at Week 40.08 ± 0.030.09 ± 0.02
Change at Week 80.09 ± 0.030.13 ± 0.02
Change at Week 120.13 ± 0.030.14 ± 0.02
Change at Week 240.17 ± 0.030.22 ± 0.03
Change at Week 360.24 ± 0.040.28 ± 0.03
Change at Week 520.29 ± 0.040.38 ± 0.03
SecondaryChange From Baseline in Forced Expiratory Flow (FEF) 25-75% at Weeks 2, 4, 8, 12, 24, 36, 52: Type 2 Inflammatory Asthma Phenotype Population

FEF is the amount of air (in liters) which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% was defined as the mean FEF between 25% and 75% of the FVC, where FVC was defined as the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. LS means and SE were derived from MMRM model with change from baseline in FEF 25-75% values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline FEF 25-75% value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · liters/second
Change From Baseline in Forced Expiratory Flow (FEF) 25-75% at Weeks 2, 4, 8, 12, 24, 36, 52: Type 2 Inflammatory Asthma Phenotype Population
liters/secondPlaceboDupilumab
Change at Week 20.11 ± 0.050.28 ± 0.04
Change at Week 40.07 ± 0.050.34 ± 0.04
Change at Week 80.10 ± 0.050.39 ± 0.04
Change at Week 120.14 ± 0.050.41 ± 0.04
Change at Week 240.16 ± 0.050.44 ± 0.04
Change at Week 360.29 ± 0.050.49 ± 0.04
Change at Week 520.29 ± 0.060.60 ± 0.04
SecondaryChange From Baseline in Forced Expiratory Flow 25-75% at Weeks 2, 4, 8, 12, 24, 36, 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

FEF is the amount of air (in liters) which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% was defined as the mean FEF between 25% and 75% of the FVC, where FVC was defined as the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. LS means and SE were derived from MMRM model with change from baseline in FE F25-75% values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, sex, ethnicity, baseline height, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline FEF 25-75% value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · liters/second
Change From Baseline in Forced Expiratory Flow 25-75% at Weeks 2, 4, 8, 12, 24, 36, 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
liters/secondPlaceboDupilumab
Change at Week 20.07 ± 0.050.29 ± 0.04
Change at Week 40.00 ± 0.050.33 ± 0.04
Change at Week 80.02 ± 0.060.40 ± 0.04
Change at Week 120.10 ± 0.050.42 ± 0.04
Change at Week 240.12 ± 0.060.47 ± 0.04
Change at Week 360.27 ± 0.060.51 ± 0.05
Change at Week 520.26 ± 0.070.65 ± 0.05
SecondaryChange From Baseline in Post-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population

Participants were assessed for post-bronchodilator FEV1 30 minutes after bronchodilator administration (200 to 400 mg \[2 to 4 puffs\] of albuterol/salbutamol or 45 to 90 micrograms \[2 to 4 puffs\] of levalbuterol/levosalbutamol). FEV1 was the volume of air (in liters) exhaled in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in post-bronchodilator FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline post-bronchodilator FEV1 value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · liters
Change From Baseline in Post-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population
litersPlaceboDupilumab
Change at Week 20.61 ± 1.261.51 ± 0.92
Change at Week 4-0.02 ± 1.152.42 ± 0.86
Change at Week 8-0.79 ± 1.212.85 ± 0.90
Change at Week 12-0.32 ± 1.232.48 ± 0.91
Change at Week 24-0.50 ± 1.312.60 ± 0.96
Change at Week 360.55 ± 1.463.15 ± 1.07
Change at Week 52-0.75 ± 1.483.62 ± 1.08
SecondaryChange From Baseline in Post-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

Participants were assessed for post-bronchodilator FEV1 30 minutes after bronchodilator administration (200 to 400 mg \[2 to 4 puffs\] of albuterol/salbutamol or 45 to 90 micrograms \[2 to 4 puffs\] of levalbuterol/levosalbutamol). FEV1 was the volume of air (in liters) exhaled in the first second of a forced expiration as measured by spirometer. LS means and SE were derived from MMRM model with change from baseline in post-bronchodilator FEV1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline post-bronchodilator FEV1 value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · liters
Change From Baseline in Post-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
litersPlaceboDupilumab
Change at Week 20.10 ± 1.490.52 ± 1.07
Change at Week 4-0.29 ± 1.351.44 ± 1.00
Change at Week 8-2.05 ± 1.311.81 ± 0.98
Change at Week 12-0.61 ± 1.442.28 ± 1.04
Change at Week 24-0.80 ± 1.542.25 ± 1.12
Change at Week 360.72 ± 1.802.87 ± 1.31
Change at Week 52-0.52 ± 1.793.13 ± 1.30
SecondaryChange From Baseline in Morning Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population

The morning asthma symptom score evaluated participant's overall asthma symptoms experienced during the previous night. It ranged from 0 (no asthma symptoms, slept through the night) to 4 (bad night, awake most of the night because of asthma), where lower scores indicate more mild symptoms and higher scores indicate more severe symptoms. LS means and SE were derived from MMRM model with change from baseline in AM asthma symptom score values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline AM asthma symptom score value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Morning Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population
score on a scalePlaceboDupilumab
Change at Week 2-0.22 ± 0.04-0.18 ± 0.03
Change at Week 4-0.29 ± 0.05-0.34 ± 0.04
Change at Week 8-0.37 ± 0.05-0.39 ± 0.04
Change at Week 12-0.34 ± 0.05-0.48 ± 0.04
Change at Week 24-0.46 ± 0.05-0.56 ± 0.04
Change at Week 36-0.48 ± 0.05-0.56 ± 0.04
Change at Week 52-0.50 ± 0.05-0.61 ± 0.04
SecondaryChange From Baseline in Evening Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population

The evening asthma symptom score evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 (very well, no asthma symptoms) to 4 (asthma very bad, unable to carry out daily activities as usual), where lower scores indicate more mild symptoms and higher scores indicate more severe symptoms. LS means and SE were derived from MMRM model with change from baseline in PM asthma symptom score values up to Week 52 as response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PM asthma symptom score value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Evening Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population
score on a scalePlaceboDupilumab
Change at Week 2-0.17 ± 0.05-0.13 ± 0.03
Change at Week 4-0.25 ± 0.05-0.29 ± 0.04
Change at Week 8-0.33 ± 0.06-0.40 ± 0.04
Change at Week 12-0.30 ± 0.06-0.45 ± 0.04
Change at Week 24-0.44 ± 0.06-0.53 ± 0.04
Change at Week 36-0.47 ± 0.06-0.55 ± 0.04
Change at Week 52-0.50 ± 0.06-0.59 ± 0.04
SecondaryChange From Baseline in Morning Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

The morning asthma symptom score evaluated participant's overall asthma symptoms experienced during the previous night. It ranged from 0 (no asthma symptoms, slept through the night) to 4 (bad night, awake most of the night because of asthma), where lower scores indicate more mild symptoms and higher scores indicate more severe symptoms. LS means and SE were derived from MMRM model with change from baseline in AM asthma symptom score values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline AM asthma symptom score value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Morning Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
score on a scalePlaceboDupilumab
Change at Week 2-0.24 ± 0.05-0.20 ± 0.04
Change at Week 4-0.32 ± 0.06-0.34 ± 0.04
Change at Week 8-0.38 ± 0.06-0.40 ± 0.05
Change at Week 12-0.33 ± 0.06-0.48 ± 0.04
Change at Week 24-0.45 ± 0.06-0.55 ± 0.04
Change at Week 36-0.46 ± 0.06-0.56 ± 0.04
Change at Week 52-0.50 ± 0.06-0.62 ± 0.04
SecondaryChange From Baseline in Evening Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

The evening asthma symptom score evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 (very well, no asthma symptoms) to 4 (asthma very bad, unable to carry out daily activities as usual), where lower scores indicate more mild symptoms and higher scores indicate more severe symptoms. LS means and SE were derived from MMRM model with change from baseline in PM asthma symptom score values up to Week 52 as response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PM asthma symptom score value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Evening Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
score on a scalePlaceboDupilumab
Change at Week 2-0.18 ± 0.05-0.15 ± 0.04
Change at Week 4-0.27 ± 0.06-0.29 ± 0.04
Change at Week 8-0.30 ± 0.06-0.41 ± 0.05
Change at Week 12-0.29 ± 0.07-0.48 ± 0.05
Change at Week 24-0.42 ± 0.06-0.53 ± 0.05
Change at Week 36-0.43 ± 0.06-0.56 ± 0.05
Change at Week 52-0.51 ± 0.06-0.60 ± 0.04
SecondaryChange From Baseline in Asthma Control Questionnaire-Interviewer Administered, 5-question Version (ACQ-5-IA) at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population

ACQ-5-IA has 5 questions, reflecting top-scoring 5 asthma symptoms: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities, shortness of breath due to asthma and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). ACQ-5-IA total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), higher scores indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-5-IA values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-5-IA value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 5-question Version (ACQ-5-IA) at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population
score on a scalePlaceboDupilumab
Change at Week 2-0.72 ± 0.09-0.77 ± 0.06
Change at Week 4-0.86 ± 0.08-1.09 ± 0.06
Change at Week 8-1.04 ± 0.09-1.24 ± 0.07
Change at Week 12-1.04 ± 0.08-1.35 ± 0.06
Change at Week 24-1.18 ± 0.08-1.46 ± 0.06
Change at Week 36-1.25 ± 0.08-1.57 ± 0.06
Change at Week 52-1.30 ± 0.07-1.70 ± 0.05
SecondaryChange From Baseline in Asthma Control Questionnaire-Interviewer Administered, 5-question Version at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

ACQ-5-IA has 5 questions, reflecting top-scoring 5 asthma symptoms: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities, shortness of breath due to asthma and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). ACQ-5-IA total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), higher scores indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-5-IA values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-5-IA value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 5-question Version at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
score on a scalePlaceboDupilumab
Change at Week 2-0.63 ± 0.11-0.76 ± 0.08
Change at Week 4-0.75 ± 0.10-1.10 ± 0.07
Change at Week 8-0.98 ± 0.10-1.27 ± 0.07
Change at Week 12-1.00 ± 0.10-1.37 ± 0.07
Change at Week 24-1.06 ± 0.09-1.48 ± 0.07
Change at Week 36-1.17 ± 0.09-1.59 ± 0.07
Change at Week 52-1.25 ± 0.08-1.71 ± 0.06
SecondaryChange From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version at Weeks 2, 4, 8, 12, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

ACQ-7-IA had 7 questions, assessed: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities, shortness of breath due to asthma and wheeze, reliever medication use, and FEV1 (% predicted). Participants recalled their previous week asthma and answered 5 symptom questions on 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). Total score:mean of scores of all 7 questions; ranging from 0 (totally controlled) to 6 (severely uncontrolled), higher score indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-7-IA values up to Week 52 as response variable and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-7-IA value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8,12, 36, 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version at Weeks 2, 4, 8, 12, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
score on a scalePlaceboDupilumab
Change at Week 2-0.50 ± 0.09-0.70 ± 0.07
Change at Week 4-0.64 ± 0.09-1.02 ± 0.06
Change at Week 8-0.83 ± 0.09-1.16 ± 0.06
Change at Week 12-0.85 ± 0.09-1.24 ± 0.06
Change at Week 36-1.01 ± 0.08-1.43 ± 0.06
Change at Week 52-1.04 ± 0.08-1.54 ± 0.06
SecondaryChange From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version at Weeks 2, 4, 8, 12, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population

ACQ-7-IA had 7 questions, assessed: frequency of nocturnal awakenings, severity of asthma symptoms in the mornings, limitation of daily activities due to asthma, shortness of breath due to asthma and wheeze, reliever medication use, and FEV1 (% predicted). Participants recalled their previous week asthma and answered 5 symptom questions on 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). Total score: mean of scores of all 7 questions; ranging from 0 (totally controlled) to 6 (severely uncontrolled), higher score indicated lower asthma control. LS means and SE were derived from MMRM model with change from baseline in ACQ-7-IA values up to Week 52 as response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline ACQ-7-IA value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8,12, 36, 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version at Weeks 2, 4, 8, 12, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population
score on a scalePlaceboDupilumab
Change at Week 2-0.60 ± 0.08-0.72 ± 0.06
Change at Week 4-0.74 ± 0.07-1.03 ± 0.05
Change at Week 8-0.91 ± 0.08-1.14 ± 0.06
Change at Week 12-0.89 ± 0.07-1.23 ± 0.05
Change at Week 36-1.09 ± 0.07-1.41 ± 0.05
Change at Week 52-1.09 ± 0.06-1.53 ± 0.05
SecondaryChange From Baseline in Number of Puffs of Reliever Medication Used Per 24 Hours at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population

Participants might be administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed. Number of reliever medication inhalations were recorded daily in electronic diary/PEF meter. When Nebulizer solutions were used as alternative delivery method, nebulizer dose was converted to number of puffs as per conversion factor: salbutamol/albuterol nebulizer solution (2.5 mg) and levosalbutamol/levalbuterol (1.25 mg) corresponds to 4 puffs. Change From Baseline in number of puffs of reliever medication used per 24 hours at specified weeks was reported. LS means and SE were derived from MMRM model with change from baseline in number of puffs of reliever medication/24 hours values up to Week 52 as response variable and treatment, age, baseline: weight group, region, eosinophil level, FeNO level, ICS dose level, visit, treatment by-visit interaction, baseline number of puffs of reliever medication/24 hours value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · puffs of reliever medication per 24 hour
Change From Baseline in Number of Puffs of Reliever Medication Used Per 24 Hours at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population
puffs of reliever medication per 24 hourPlaceboDupilumab
Change at Week 2-0.78 ± 0.17-0.65 ± 0.12
Change at Week 4-0.99 ± 0.17-1.02 ± 0.13
Change at Week 8-1.24 ± 0.17-1.28 ± 0.13
Change at Week 12-0.93 ± 0.18-1.41 ± 0.13
Change at Week 24-1.43 ± 0.17-1.61 ± 0.13
Change at Week 36-1.37 ± 0.17-1.60 ± 0.13
Change at Week 52-1.59 ± 0.16-1.72 ± 0.12
SecondaryChange From Baseline in Number of Puffs of Reliever Medication Used Per 24 Hours at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

Participants might be administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed. Number of reliever medication inhalations were recorded daily in electronic diary/PEF meter. When Nebulizer solutions were used as alternative delivery method, nebulizer dose was converted to number of puffs as per conversion factor: salbutamol/albuterol nebulizer solution (2.5 mg) and levosalbutamol/levalbuterol (1.25 mg) corresponds to 4 puffs. Change From Baseline in number of puffs of reliever medication used per 24 hours at specified weeks was reported. LS means and SE were derived from MMRM model with change from baseline in number of puffs of reliever medication/24 hours values up to Week 52 as response variable and treatment, age, baseline: weight group, region, eosinophil level, FeNO level, ICS dose level, visit, treatment by-visit interaction, baseline number of puffs of reliever medication/24 hours value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · puffs of reliever medication per 24 hour
Change From Baseline in Number of Puffs of Reliever Medication Used Per 24 Hours at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
puffs of reliever medication per 24 hourPlaceboDupilumab
Change at Week 2-0.75 ± 0.19-0.67 ± 0.14
Change at Week 4-1.02 ± 0.20-1.01 ± 0.15
Change at Week 8-1.15 ± 0.20-1.29 ± 0.14
Change at Week 12-1.02 ± 0.20-1.39 ± 0.14
Change at Week 24-1.25 ± 0.20-1.53 ± 0.15
Change at Week 36-1.20 ± 0.21-1.49 ± 0.15
Change at Week 52-1.45 ± 0.19-1.58 ± 0.14
SecondaryChange From Baseline in Number of Nocturnal Awakenings Per Night at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population

Participants recorded every morning the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night. Change from baseline in number of nocturnal awakenings per night at specified weeks was reported. LS means and SE were derived from MMRM model with change from baseline in number of nocturnal awakenings values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline number of nocturnal awakenings value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · nocturnal awakenings per night
Change From Baseline in Number of Nocturnal Awakenings Per Night at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population
nocturnal awakenings per nightPlaceboDupilumab
Change at Week 2-0.13 ± 0.03-0.13 ± 0.02
Change at Week 4-0.16 ± 0.03-0.21 ± 0.03
Change at Week 8-0.21 ± 0.04-0.21 ± 0.03
Change at Week 12-0.17 ± 0.04-0.26 ± 0.03
Change at Week 24-0.23 ± 0.03-0.29 ± 0.02
Change at Week 36-0.25 ± 0.03-0.29 ± 0.02
Change at Week 52-0.26 ± 0.03-0.32 ± 0.02
SecondaryChange From Baseline in Number of Nocturnal Awakenings Per Night at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

Participants recorded every morning the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night. Change from baseline in number of nocturnal awakenings per night at specified weeks was reported. LS means and SE were derived from MMRM model with change from baseline in number of nocturnal awakenings values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline number of nocturnal awakenings value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 52
Reported as:
Least squares mean · nocturnal awakenings per night
Change From Baseline in Number of Nocturnal Awakenings Per Night at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
nocturnal awakenings per nightPlaceboDupilumab
Change at Week 2-0.15 ± 0.03-0.12 ± 0.02
Change at Week 4-0.19 ± 0.04-0.21 ± 0.03
Change at Week 8-0.22 ± 0.05-0.20 ± 0.04
Change at Week 12-0.16 ± 0.04-0.25 ± 0.03
Change at Week 24-0.21 ± 0.04-0.28 ± 0.03
Change at Week 36-0.25 ± 0.04-0.27 ± 0.03
Change at Week 52-0.26 ± 0.03-0.32 ± 0.02
SecondaryChange From Baseline in Pediatric Asthma Quality of Life (QoL) Questionnaire With Standardized Activities-Interviewer Administered (PAQLQ[S] IA) Scores at Weeks 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population

PAQLQ(S)-IA, a disease-specific, interviewer-administered QoL questionnaire designed to measure functional impairments that are most important to children \>=7 years with asthma. The PAQLQ(S)-IA comprises of 23 items in 3 domains: symptoms (10 items), activity limitation (5 items) and emotional function (8 items). Each item was scored on a 7-point likert scale (1=maximal impairment to 7=no impairment). 23 items of questionnaire were averaged to produce 1 overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all), higher scores indicated better quality of life. LS means and SE were derived from MMRM model with change from baseline in PAQLQ(S)-IA global score values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PAQLQ(S)-IA global score value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 12, 24, 36, 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Pediatric Asthma Quality of Life (QoL) Questionnaire With Standardized Activities-Interviewer Administered (PAQLQ[S] IA) Scores at Weeks 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population
score on a scalePlaceboDupilumab
Change at Week 120.97 ± 0.091.08 ± 0.07
Change at Week 241.11 ± 0.091.30 ± 0.07
Change at Week 361.15 ± 0.091.48 ± 0.07
Change at Week 521.19 ± 0.081.53 ± 0.06
SecondaryChange From Baseline in Pediatric Asthma Quality of Life Questionnaire With Standardized Activities-Interviewer Administered Scores at Weeks 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

PAQLQ(S)-IA, a disease-specific, interviewer-administered QoL questionnaire designed to measure functional impairments that are most important to children \>=7 years with asthma. The PAQLQ(S)-IA comprises of 23 items in 3 domains: symptoms (10 items), activity limitation (5 items) and emotional function (8 items). Each item was scored on a 7-point likert scale (1=maximal impairment to 7=no impairment). 23 items of questionnaire were averaged to produce 1 overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all), higher scores indicated better quality of life. LS means and SE were derived from MMRM model with change from baseline in PAQLQ(S)-IA global score values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, baseline ICS dose level, visit, treatment by-visit interaction, baseline PAQLQ(S)-IA global score value and baseline-by-visit interaction as covariates.

Time frame:
Baseline, Weeks 12, 24, 36, 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Pediatric Asthma Quality of Life Questionnaire With Standardized Activities-Interviewer Administered Scores at Weeks 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
score on a scalePlaceboDupilumab
Change at Week 120.90 ± 0.101.11 ± 0.08
Change at Week 241.06 ± 0.101.36 ± 0.08
Change at Week 361.07 ± 0.101.51 ± 0.08
Change at Week 521.23 ± 0.091.56 ± 0.07
SecondaryHealthcare Resource Utilization (HCRU): Number of School and Work Days Missed Due to LOAC: Type 2 Inflammatory Asthma Phenotype Population

The number of days missed from school by the participant and the number of days missed from work by the caregiver of participant due to a LOAC were collected in the electronic-case report form (eCRF). Cumulative number of missed days (school days and work days) up to week 52 were computed and summarized using mean and standard deviation (SD).

Time frame:
Baseline to Week 52
Reported as:
Mean · days
Healthcare Resource Utilization (HCRU): Number of School and Work Days Missed Due to LOAC: Type 2 Inflammatory Asthma Phenotype Population
daysPlaceboDupilumab
Number of missed school days2.1 ± 4.21.0 ± 2.3
Number of missed work days0.7 ± 1.90.2 ± 0.8
SecondaryHealthcare Resource Utilization: Number of School and Work Days Missed Due to LOAC: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

The number of days missed from school by the participant and the number of days missed from work by the caregiver of participant due to a LOAC were collected in the eCRF. Cumulative number of missed days (school days and work days) up to week 52 were computed and summarized using mean and SD.

Time frame:
Baseline to Week 52
Reported as:
Mean · days
Healthcare Resource Utilization: Number of School and Work Days Missed Due to LOAC: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
daysPlaceboDupilumab
Number of missed school days2.0 ± 3.50.9 ± 2.0
Number of missed work days0.6 ± 1.80.2 ± 0.7
SecondaryHealthcare Resource Utilization: Percentage of Participants Who Had Missed Greater Than or Equal to 5 School/Work Days Due to LOAC: Type 2 Inflammatory Asthma Phenotype Population

The number of days missed from school for the participant and the missed number of days from work for the caregiver due to a LOAC were collected in the eCRF. The percentage of participants who had at least 5 days (school days and work days) missed due to LOAC over the study period was reported.

Time frame:
Baseline to Week 52
Reported as:
Number · percentage of participants
Healthcare Resource Utilization: Percentage of Participants Who Had Missed Greater Than or Equal to 5 School/Work Days Due to LOAC: Type 2 Inflammatory Asthma Phenotype Population
percentage of participantsPlaceboDupilumab
Percentage of participants with >=5 missed school days17.59.7
Percentage of participants with >=5 missed work days70.8
SecondaryHealthcare Resource Utilization: Percentage of Participants Who Had Missed Greater Than or Equal to 5 School/Work Days Due to LOAC: Baseline Blood Eosinophils >=300 Cells Per Microliter Population

The number of days missed from school for the participant and the missed number of days from work for the caregiver due to a LOAC were collected in the eCRF. The percentage of participants who had at least 5 days (school days and work days) missed due to LOAC over the study period was reported.

Time frame:
Baseline to Week 52
Reported as:
Number · percentage of participants
Healthcare Resource Utilization: Percentage of Participants Who Had Missed Greater Than or Equal to 5 School/Work Days Due to LOAC: Baseline Blood Eosinophils >=300 Cells Per Microliter Population
percentage of participantsPlaceboDupilumab
Percentage of participants with >=5 missed school days17.98.6
Percentage of participants with >=5 missed work days60.6
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

Adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and did not necessary have to had a causal relationship with treatment.TEAEs were defined as AEs that developed or worsened in grade or became serious during TEAE period which was defined as the period from the time of first dose of study drug to the end of post-treatment period. A serious adverse events (SAE) was any untoward medical occurrence that at any dose resulted in: death; or life-threatening experience; or required inpatient hospitalization or prolongation of existing hospitalization; or resulted in persistent or significant disability/incapacity; or was a congenital anomaly/birth defect or a medically important event. TEAEs included both SAEs and non-SAEs.

Time frame:
From Baseline up to Week 64
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsPlaceboDupilumab
Any TEAE107225
TESAE613
SecondaryPharmacokinetics (PK) Assessment: Functional Dupilumab Concentration in Serum

Data for this outcome measure was planned to be collected and analyzed separately for dupilumab 100 mg and 200 mg dose and not planned to be collected and analyzed for placebo arm.

Time frame:
Baseline, Weeks 6, 12, 24, 52, 64
Reported as:
Geometric mean · nanograms per milliliter
Pharmacokinetics (PK) Assessment: Functional Dupilumab Concentration in Serum
nanograms per milliliterDupilumab 100mg q2wDupilumab 200mg q2w
Baseline0.00 ± 948.6830.00 ± 0.000
Week 628566.81 ± 47.11450269.81 ± 46.667
Week 1237741.97 ± 46.51663476.17 ± 44.444
Week 2442283.09 ± 47.91049525.35 ± 52.806
Week 5241467.97 ± 49.36845295.35 ± 56.990
Week 6439.00 ± 0.00039.00 ± 0.000
SecondaryPercentage of Participants With Treatment Emergent Antidrug Antibodies (ADA) Response

ADA response was categorized as: treatment emergent and treatment boosted response. 1) Treatment emergent was defined as an ADA positive response in the assay post first dose, when baseline results were negative or missing. 2) Treatment boosted was defined as: an ADA positive response in the assay post first dose that was greater-than or equal to 4-fold over baseline titer levels, when baseline results were positive. The criteria for positive was defined as "30 to \> 10,000", where low titer (\< 1,000); moderate (1,000 \<= titer \<= 10,000) and high titer (\> 10,000).

Time frame:
From Baseline up to Week 64
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent Antidrug Antibodies (ADA) Response
percentage of participantsPlaceboDupilumab 100mg q2wDupilumab 200mg q2w
Treatment-emergent ADA3.04.47.3
Treatment-boosted ADA000
SecondaryPercentage of Participants With Seroconversion

Seroconversion was defined as a post-vaccination titer \>=40 (1/dilution) for those with a pre-vaccination titer \<10 (1/dilution), or a \>= 4-fold increase in post-vaccination titer for those with a pre-vaccination titer \>=10 (1/dilution).

Time frame:
From Baseline up to Week 64
Reported as:
Number · percentage of participants
Percentage of Participants With Seroconversion
percentage of participantsPlaceboDupilumab
Percentage of Participants With Seroconversion62.579.6

Adverse events

Collected over All AEs were collected from signature of the informed consent form up to end of post treatment period (i.e., up to Week 64) regardless of seriousness or relationship to IMP.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/134 (0%)6/134 (4.5%)89/134 (66.4%)
Dupilumab0/271 (0%)13/271 (4.8%)161/271 (59.4%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventPlaceboDupilumab
AsthmaRespiratory, thoracic and mediastinal disorders0/1344/271
Immune ThrombocytopeniaBlood and lymphatic system disorders1/1340/271
Anaphylactic ReactionImmune system disorders1/1340/271
GastroenteritisInfections and infestations1/1340/271
Gastrointestinal Viral InfectionInfections and infestations1/1340/271
Lymphadenitis ViralInfections and infestations1/1340/271
Parainfluenzae Virus InfectionInfections and infestations1/1340/271
Partial SeizuresNervous system disorders1/1340/271
AtelectasisRespiratory, thoracic and mediastinal disorders1/1340/271
BronchospasmRespiratory, thoracic and mediastinal disorders1/1340/271
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboDupilumab
NasopharyngitisInfections and infestations29/13450/271
Upper Respiratory Tract InfectionInfections and infestations18/13435/271
Injection Site ErythemaGeneral disorders13/13435/271
Viral Upper Respiratory Tract InfectionInfections and infestations13/13433/271
Rhinitis AllergicRespiratory, thoracic and mediastinal disorders16/13416/271
BronchitisInfections and infestations14/13417/271
PharyngitisInfections and infestations14/13423/271
Injection Site OedemaGeneral disorders7/13428/271
InfluenzaInfections and infestations12/13420/271
HeadacheNervous system disorders10/13418/271

Baseline characteristics

Analysis was performed on intent to treat population which included all randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboDupilumabTotal
Mean8.9 ± 1.68.9 ± 1.78.9 ± 1.6
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDupilumabTotal
Female4898146
Male87175262
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboDupilumabTotal
Caucasian/White118242360
Black/of African descent91120
Asian/Oriental022
American Indian or Alaska Native011
Other81725
08

Study locations

99 sites
  • Investigational Site Number 840031
    Birmingham, Alabama 35209, United States
  • Investigational Site Number 840002
    Gilbert, Arizona 85234, United States
  • Investigational Site Number 840012
    Tucson, Arizona 85724-5030, United States
  • Investigational Site Number 840001
    Rolling Hills Estates, California 90274, United States
  • Investigational Site Number 840036
    Owensboro, Kentucky 42301, United States
  • Investigational Site Number 840016
    Ann Arbor, Michigan 48106, United States
  • Investigational Site Number 840006
    Saint Louis, Missouri 63110-1077, United States
  • Investigational Site Number 840022
    Lincoln, Nebraska 68505, United States
  • Investigational Site Number 840023
    Great Neck, New York 11021, United States
  • Investigational Site Number 840035
    New York, New York 00000, United States
  • Investigational Site Number 840013
    New York, New York 10032, United States
  • Investigational Site Number 840007
    Rochester, New York 14607, United States
  • Investigational Site Number 840004
    Charlotte, North Carolina 28277, United States
  • Investigational Site Number 840021
    Durham, North Carolina 27710, United States
  • Investigational Site Number 840008
    Cincinnati, Ohio 45229, United States
  • Investigational Site Number 840024
    Edmond, Oklahoma 73034, United States
  • Investigational Site Number 840003
    San Antonio, Texas 78229, United States
  • Investigational Site Number 840018
    La Crosse, Wisconsin 54601, United States
  • Investigational Site Number 032004
    Buenos Aires, B1602DQD, Argentina
  • Investigational Site Number 032003
    Buenos Aires, C1121ABE, Argentina
  • Investigational Site Number 032002
    Caba, C1122AAK, Argentina
  • Investigational Site Number 032001
    Caba, C1414AIF, Argentina
  • Investigational Site Number 032006
    Mendoza, 5500, Argentina
  • Investigational Site Number 036001
    Campbelltown, 2560, Australia
  • Investigational Site Number 036005
    North Adelaide, 5006, Australia
  • Investigational Site Number 036003
    Parkville/Melbourne, 3052, Australia
  • Investigational Site Number 036002
    South Brisbane, 4101, Australia
  • Investigational Site Number 076008
    Blumenau, 89030-100, Brazil
  • Investigational Site Number 076001
    Porto Alegre, 90020-090, Brazil
  • Investigational Site Number 076007
    Porto Alegre, 90610-000, Brazil
  • Investigational Site Number 076003
    Sao Paulo, 02189-010, Brazil
  • Investigational Site Number 076002
    Sao Paulo, 04037-002, Brazil
  • Investigational Site Number 076004
    Sao Paulo, 05403-000, Brazil
  • Investigational Site Number 076006
    Sorocaba, 18040-425, Brazil
  • Investigational Site Number 124004
    Edmonton, T6G 2B7, Canada
  • Investigational Site Number 124002
    Hamilton, L8S1G5, Canada
  • Investigational Site Number 124001
    Montreal, H3T 1C5, Canada
  • Investigational Site Number 124003
    Quebec, G1V 4W2, Canada
  • Investigational Site Number 152003
    Santiago, 7560994, Chile
  • Investigational Site Number 152005
    Santiago, 838-0418, Chile
  • Investigational Site Number 152009
    Santiago, 8380453, Chile
  • Investigational Site Number 152001
    Valdivia, Chile
  • Investigational Site Number 152007
    Viña Del Mar, 2520024, Chile
  • Investigational Site Number 152002
    Viña Del Mar, 2520594, Chile
  • Investigational Site Number 170004
    Antioquia, 050010, Colombia
  • Investigational Site Number 170002
    Cali, 760043, Colombia
  • Investigational Site Number 348006
    Budapest, 1089, Hungary
  • Investigational Site Number 348002
    Gyula, 5700, Hungary
  • Investigational Site Number 348012
    Mezőkövesd, 3400, Hungary
  • Investigational Site Number 348005
    Szeged, 6720, Hungary
  • Investigational Site Number 348008
    Szigetvár, 7900, Hungary
  • Investigational Site Number 348001
    Székesfehérvár, 8000, Hungary
  • Investigational Site Number 348003
    Töröbálint, 2045, Hungary
  • Investigational Site Number 348007
    Zalaegerszeg, 8900, Hungary
  • Investigational Site Number 380007
    Catania, 95123, Italy
  • Investigational Site Number 380003
    Firenze, 50139, Italy
  • Investigational Site Number 380004
    Padova, 35128, Italy
  • Investigational Site Number 380005
    Roma, 00146, Italy
  • Investigational Site Number 380001
    Verona, 37126, Italy
  • Investigational Site Number 440002
    Kaunas, LT-50161, Lithuania
  • Investigational Site Number 440005
    Siauliai, LT-76231, Lithuania
  • Investigational Site Number 440003
    Utena, LT-28151, Lithuania
  • Investigational Site Number 440001
    Vilnius, LT-08406, Lithuania
  • Investigational Site Number 440004
    Vilnius, LT-09108, Lithuania
  • Investigational Site Number 484006
    Chihuahua, 31000, Mexico
  • Investigational Site Number 484004
    Chihuahua, 31200, Mexico
  • Investigational Site Number 484003
    Durango, 34080, Mexico
  • Investigational Site Number 484001
    Monterrey, 64460, Mexico
  • Investigational Site Number 484002
    Veracruz, 91910, Mexico
  • Investigational Site Number 616001
    Lodz, 90-329, Poland
  • Investigational Site Number 616002
    Poznan, 60-693, Poland
  • Investigational Site Number 642001
    Bucuresti, 020395, Romania
  • Investigational Site Number 643006
    Moscow, 119333, Russian Federation
  • Investigational Site Number 643004
    Perm, 614066, Russian Federation
  • Investigational Site Number 643005
    Saint Petersburg, 191144, Russian Federation
  • Investigational Site Number 643002
    Saint Petersburg, 193312, Russian Federation
  • Investigational Site Number 643001
    Saint-Petersburg, 194100, Russian Federation
  • Investigational Site Number 643003
    Saint-Petersburg, 196240, Russian Federation
  • Investigational Site Number 710004
    Cape Town, 7500, South Africa
  • Investigational Site Number 710001
    Cape Town, 7700, South Africa
  • Investigational Site Number 724001
    Barcelona, 08035, Spain
  • Investigational Site Number 724006
    Esplugues De Llobregat, 08950, Spain
  • Investigational Site Number 724005
    Pozuelo De Alarcón, 28223, Spain
  • Investigational Site Number 724002
    Santiago De Compostela, 15706, Spain
  • Investigational Site Number 724003
    Valencia, 46017, Spain
  • Investigational Site Number 792005
    Adana, Turkey
  • Investigational Site Number 792008
    Ankara, 06500, Turkey
  • Investigational Site Number 792001
    Ankara, Turkey
  • Investigational Site Number 792006
    Bursa, Turkey
  • Investigational Site Number 792003
    İstanbul, Turkey
  • Investigational Site Number 792004
    Istanbul, Turkey
  • Investigational Site Number 804007
    Chernivtsi, 58023, Ukraine
  • Investigational Site Number 804004
    Dnipro, 49101, Ukraine
  • Investigational Site Number 804011
    Ivano-Frankivsk, 76014, Ukraine
  • Investigational Site Number 804005
    Kharkiv, 61093, Ukraine
  • Investigational Site Number 804008
    Kryvyi Rig, 50082, Ukraine
  • Investigational Site Number 804001
    Kyiv, 03115, Ukraine
  • Investigational Site Number 804002
    Zaporizhzhya, 69063, Ukraine
  • Investigational Site Number 804003
    Zaporizhzhya, 69076, Ukraine
09

References and documents

Publications

  • Bacharier LB, Maspero JF, Katelaris CH, Fiocchi AG, Gagnon R, de Mir I, Jain N, Sher LD, Mao X, Liu D, Zhang Y, Khan AH, Kapoor U, Khokhar FA, Rowe PJ, Deniz Y, Ruddy M, Laws E, Patel N, Weinreich DM, Yancopoulos GD, Amin N, Mannent LP, Lederer DJ, Hardin M; Liberty Asthma VOYAGE Investigators. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. N Engl J Med. 2021 Dec 9;385(24):2230-2240. doi: 10.1056/NEJMoa2106567. PubMed 34879449 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Aug 2020, 40 months.

Results were first posted in Oct 2021, 1 year 1 month after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 40 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2016
First posted
Oct 31, 2016
StartActual
Apr 21, 2017
Primary completionActual
Aug 26, 2020
CompletionActual
Aug 26, 2020
Results first posted
Oct 20, 2021
Last update
Mar 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02948959
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 31, 2016
Start date
Apr 21, 2017
Primary completion
Aug 26, 2020
Completion
Aug 26, 2020
Results posted
Oct 20, 2021
Last update
Mar 28, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion